StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Inhibikase Therapeutics's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $276.46K in fiscal 2020.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$110.52K-26.4%
FY2023Dec 31, 2023$150.10K+2.9%
FY2022Dec 31, 2022$145.84K–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$276.46K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$37.94K-75.1%
Q1 FY2025Mar 31, 2025$74.77K-50.5%
Q4 FY2024Dec 31, 2024$110.52K-26.4%
Q3 FY2024Sep 30, 2024$145.21K-2.6%
Q2 FY2024Jun 30, 2024$152.22K+2.9%
Q1 FY2024Mar 31, 2024$151.16K+2.9%
Q4 FY2023Dec 31, 2023$150.10K+2.9%
Q3 FY2023Sep 30, 2023$149.03K+4.9%
Q2 FY2023Jun 30, 2023$147.97K–
Q1 FY2023Mar 31, 2023$146.90K-41.0%
Q4 FY2022Dec 31, 2022$145.84K-41.4%
Q3 FY2022Sep 30, 2022$142.05K-48.6%
Q4 FY2021Dec 31, 2021$0–
Q2 FY2021Jun 30, 2021$248.91K–
Q1 FY2021Mar 31, 2021$248.91K–
Q4 FY2020Dec 31, 2020$276.46K–

More Inhibikase Therapeutics figures

See a number that looks wrong?